OmnixMedical

@MedicalOmnix

Omnix Medical is dedicated to the development of novel antimicrobial pharmaceuticals against drug-resistant bacteria.

Vrijeme pridruživanja: studeni 2019.

Tweetovi

Blokirali ste korisnika/cu @MedicalOmnix

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @MedicalOmnix

  1. 3. velj

    but “…the progress we see is being overshadowed by our increasing reliance on just a handful of companies. We can’t take their commitment for granted. It is not too late to prevent irreparable damage to the global supply of antibiotic medicines and vaccines,” says Jayasree Iyer

    Prikaži ovu nit
    Poništi
  2. 3. velj

    An important report from . The 2020 Antimicrobial Resistance Benchmark has evaluated how the most important players in the antibiotic market are addressing the rise of resistance and the global need for appropriate access to antibiotics ...

    Prikaži ovu nit
    Poništi
  3. proslijedio/la je Tweet
    23. sij

    New from : WHO reports that, since 2017, 8 new antibiotics have been approved, but only two meet at least one innovation criteria, and the rest are derivatives of known antibiotic classes + warns that the bulk of R&D is being carried out by just a few companies

    Poništi
  4. proslijedio/la je Tweet
    23. sij

    Risk of pandemics? Rising. Drugmakers’ ability to respond? It may be falling, writes via

    Poništi
  5. 26. sij
    Prikaži ovu nit
    Poništi
  6. 26. sij

    By mimicking insect immunity, OMN6 will save the lives of millions suffering from infections involving antibiotic-resistant bacteria. Watch us as we continue to develop this game-changing drug and win the war against infectious disease.

    Prikaži ovu nit
    Poništi
  7. 26. sij

    Omnix Medical's CSO, Dr. Niv Bachnoff gave an outstanding presentation to a full house at during which was very well-received!

    Prikaži ovu nit
    Poništi
  8. proslijedio/la je Tweet
    23. sij

    💊As remains to be a hot topic in health sector worldwide. Pharmaceutical companies are still not increasing the speed to discover new effective And new available are still developing resistance .let us increase awareness concerning with

    Poništi
  9. proslijedio/la je Tweet

    Improving antibiotic use will save lives and help us combat .

    Poništi
  10. proslijedio/la je Tweet

    Did you miss our updated visuals for the new report? Download 3D images, infographics, illustrations & more on here: .

    Poništi
  11. proslijedio/la je Tweet
    4. sij

    Omnix Medical Ltd. OMN6, currently in IND-enabling studies, is developed for the treatment of severe or life-threatening Hospital/Ventilator-Associated Bacterial Pneumoniae (HABP / VABP)

    Poništi
  12. proslijedio/la je Tweet

    As part of the , Opal Biosciences, , Omnix Medical, and commit to research and develop new pharmaceuticals to treat life-threatening and hard-to-treat infections. Learn more:

    Poništi
  13. proslijedio/la je Tweet
    4. sij

    Omnix Medical Ltd. OMN6, currently in IND-enabling studies, is developed for the treatment of severe or life-threatening Hospital/Ventilator-Associated Bacterial Pneumoniae (HABP / VABP)

    Poništi
  14. 28. pro 2019.

    Omnix is looking for a strategic partner and investor to bring OMN6 to clinical dev. The Omnix team looks forward to meeting you at in SF and will be presenting at on 1/13. DM to schedule a meeting

    Prikaži ovu nit
    Poništi
  15. 28. pro 2019.

    The company’s lead drug – OMN6 – targets . OMN6 is an antimicrobial peptide for the treatment of A.baumannii, an ESKAPE pathogen. OMN6 is effective where standard of care drugs fail. It will shorten hospitalization time and reduce additional healthcare costs.

    Prikaži ovu nit
    Poništi
  16. 28. pro 2019.

    Inspired by the innate immune system of insects, employing a strategy that has been proven very efficient for 250 million years, Omnix Medical is developing an arsenal of novel antibiotic agents targeting multidrug-resistant bacteria.

    Prikaži ovu nit
    Poništi
  17. 28. pro 2019.

    Modern medicine relies on antibiotics. 1/2 of all hospitalized patients receive at least 1 antimicrobial drug on a given day, 25% take 2+. It's difficult to envisage a world wo antibiotic drugs. Yet, AMR is rapidly spreading rendering many antimicrobial drugs useless.

    Prikaži ovu nit
    Poništi
  18. proslijedio/la je Tweet
    20. pro 2019.

    Last week, I wrote about how better communication can improve how people engage with the issue of drug resistance, and strengthen efforts to . Read about how this work has changed the language I use at

    Poništi
  19. 23. pro 2019.

    Omnix is looking for a strategic partner and investor to bring OMN6 to clinical development. We are available to meet at and will be presenting at on Jan. 13. DM to schedule a partnering meeting.

    Prikaži ovu nit
    Poništi
  20. 23. pro 2019.

    Omnix Medical is developing OMN6, an antimicrobial peptide for the treatment of Acinetobacter baumannii, an ESKAPE pathogen. OMN6 is effective where standard of care drugs fail. OMN6 will shorten hospitalization time and reduce additional healthcare costs.

    Prikaži ovu nit
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·